Glycoprotein,Uniprot number,Function,Plasma concentration range (mg/mL),Avg. plasma concentration (mg/mL),N-glycosylation sites,Site occupancy (%),Glycan species,Changes under disease or inflammation,Changes with age,Glycosylation references (numbered)
Alpha-1-acid glycoprotein,P02763; P19652,Transport of lipophilic compounds,0.36–1.46,0.77,Overall,,A3G3S3 (33.5 %); A4G4S4 (19.5 %); A3FG3S3 (9 %); A4G4S3 (8.2 %); A3G3S2 (5 %); A2G2S2 (4.5 %); A4G4S2 (4 %); A4FG4S4 (2.5 %),"Conc_, F_, S_",Conc_ for females,"[44, 45, 46, 47, 48, 49, 50, 51]"
,,,,,Asn33,,A3G3S3 (60 %); A3FG3S3 (20 %); A3G3S2 (12.5 %),,,
,,,,,Asn56,,A3G3S3 (55 %); A2G2S2 (22.5 %); A3FG3S3 (12.5 %); A3G3S2 (10 %);,,,
,,,,,Asn72,,A4G4S4 (30 %); A4G4S3 (15 %); A3G3S3 (15 %); A4G4S2 (10 %); A4FG4S3 (5 %); A4FG4S4 (5 %),,,
,,,,,Asn93,,A4G4S4 (22.5 %); A4G4S3 (20 %); A3G3S3 (17.5 %); A4FG4S4 (7.5 %); A4FG3S3 (7.5 %); A3FG3S3 (7.5 %); A4G4S2 (7.5 %),,,
,,,,,Asn103,,A4G4S4 (45 %); A3G3S3 (20 %); A4G4S2 (10 %); A4G4S3 (7.5 %); A3FG3S3 (5 %),,,
Alpha-1-antitripsin,P01009,Serine protease inhibitor,1.1,1.1,Overall,,A2G2S2 (81 %); A3G3S3 (9.8 %); A3FG3S3 (5.6 %); FA2G2S2 (3.6 %),"Conc_, complex",Glycosylation_ except A2G1 and A3FG2S2_,"[52, 53, 54, 55, 56, 57]"
,,,,,Asn70,,A2G2S2 (91.3 %); FA2G2S2 (8.6 %),,,
,,,,,Asn107,,A2G2S2 (52.5 %); A3G3S3 (29.5 %); A3FG3S3 (16.7 %); FA2G2S2 (1.5 %),,,
,,,,,Asn271,,A2G2S2 (99.3 %); FA2G2S2 (0.7 %),,,
Alpha-1B-glycoprotein,P04217,"Uncertain, likely inflammation",0.22,0.22,Overall,,A2G2S1 (100 %),,,"[58, 59, 60, 61, 62]"
,,,,,Asn44,,,,,
,,,,,Asn179,,,,,
,,,,,Asn363,,A2G2S1 (100 %),,,
,,,,,Asn371,,,,,
Alpha-2-HS-glycoprotein,P02765,"Phosphate and calcium scavenger, metalloprotease protection",0.3–0.6,0.45,Overall,,A2G2S2 (96 %); FA2G2S2 (4 %),"Conc_, (F)A3G3S3_, A2G2S2_",,"[63, 64, 65, 66, 67, 68]"
,,,,,Asn156,,,Glycosylation __,,
,,,,,Asn176,,,,,
Alpha-2-macrogobulin,P01023,Protease scavenger,1–2,1.2,Overall,,A2G2S2 (35 %); A2G2S1 (35 %); FA2G2S2 (15 %); FA2G2S1 (15 %); M5-7 (8 %),"General _, Man_, G_",,"[59, 60, 67, 69, 70, 71, 72, 73, 74]"
,,,,,Asn55,,A2G2S2; FA2G2S2,,,
,,,,,Asn70,,A2G2S2,,,
,,,,,Asn247,,A2G2S2,,,
,,,,,Asn396,,A2G2S2,,,
,,,,,Asn410,,A2G2S2,,,
,,,,,Asn869,,Man5-7,,,
,,,,,Asn991,,A2G2S2,,,
,,,,,Asn1424,,A2G2S2; FA2G2S2,,,
Antithrombin-III,P01008,"Serine protease inhibitor, coagulation",0.15,0.15,Overall,,A2G2S2 (85 %); A2G2S1 (15 %),"Conc_ (thrombosis), FA_",,"[75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86]"
,,,,,Asn128,,A2G2S2; A2G2S1,,,
,,,,,Asn167,,A2G2S2; A2G2S1; A3G3S3,,,
,,,,,Asn187,,A2G2S2; A2G2S1; FA2G2S2; A3G3S3,,,
,,,,,Asn224,,A2G2S2; A2G2S1; A3G3S2,,,
Apolipoprotein B-100,P04114,Cholesterol transport (LDL),0.5,0.5,Overall,,A2G2S1 (29.2 %); A2G2S2 (23.6 %); Man9 (8.6 %); A2G2 (7.2 %); Man5 (6.9 %),,,"[11, 87, 88, 89, 90]"
,,,,,Asn34,0 %,---,,,
,,,,,Asn185,,Man5-9,,,
,,,,,Asn983,,A2G2S1; A2G2S2,,,
,,,,,Asn1368,,Man5-9,,,
,,,,,Asn1377,,Man5-9,,,
,,,,,Asn1523,,Man5-9; Hy; A1G1S1; A2G2S1; A2G2S2,,,
,,,,,Asn2239,,A2G2S1; A2G2S2,,,
,,,,,Asn2560,0 %,---,,,
,,,,,Asn2779,,A2G2S1; A2G2S2,,,
,,,,,Asn2982,,A2G2S1; A2G2S2,,,
,,,,,Asn3101,,A2G2S1; A2G2S2,,,
,,,,,Asn3224,,A2G2S1; A2G2S2,,,
,,,,,Asn3336,,Man5-9,,,
,,,,,Asn3358,,Man5-9,,,
,,,,,Asn3411,,Man5-9; Hy; A1G1S1; A2G2S1; A2G2S2,,,
,,,,,Asn3465,,A2G2S1; A2G2S2,,,
,,,,,Asn3895,,A2G2S2; A3G3S3,,,
,,,,,Asn4237,,A2G2S1; A2G2S2,,,
,,,,,Asn4431,,A2G2S1; A2G2S2,,,
Apolipoprotein D,P05090,Cholesterol transport (HDL),0.1,0.1,Overall,,A2FG2S2; A3G3S3,Conc_,Conc_(Females),"[59, 60, 62, 67, 91, 92, 93]"
,,,,,Asn65,,A2G2S2; A3G3S2; A3G3S3; A4G4S4,,,
,,,,,Asn98,,A2G2FS1; A2G2S2; A2FG2S2; A3FG3S2; A3FG3S3; A4FG4S3,,,
Apolipoprotein F,Q13790,Cholesterol transport (VLDL),0.073–0.096 (F-M),0.0845,Overall,,,,,"[94, 95, 96]"
,,Proprotein,,,Asn118,,Man5-9,,,
,,Proprotein,,,Asn139,,Man5-9,,,
,,,,,Asn267,,,,,
Beta-2-glycoprotein 1,P02749,Scavenger of negatively charged compounds,0.2,0.2,Overall,,A2G2S2 (58 %); A3G3S3 (28.5 %); A2G2S1 (6.5 %); A3G3S2 (5 %),"Conc_, A3S_, A2G2S2_",Conc_,"[59, 97, 98, 99, 100, 101, 102]"
,,,,,Asn162,,A2G2S2 (67 %); A3G3S3 (22 %); A2G2S1 (5 %); A3G3S2 (3 %),"A3_, A2_",,
,,,,,Asn183,,A2; A3,,,
,,,,,Asn193,,A2G2S2 (49 %); A3G3S3 (35 %); A2G2S1 (8 %); A3G3S2 (7 %),"A3_, A2_",,
,,,,,Asn253,,A2; A3,,,
Ceruloplasmin,P00450,Copper dependent iron oxidation (Fe2+ to Fe3+),0.15–0.96,0.355,Overall,,A2G2S2 (62.75 %); FA2G2S2 (14.5 %); A3G3S3 (13.5 %); A3G3FS3 (7.25 %),Conc_,,"[59, 103, 104, 105]"
,,,,,Asn138,,A2G2S2 (49 %); FA2G2S2 (26 %); A3G3S3 (12 %); A3FG3S3 (10 %); FA3FG3S3 (3 %),,,
,,,,,Asn227,0 %,---,,,
,,,,,Asn358,,A2G2S2 (83 %); FA2G2S2 (12 %); A3G3S3 (5 %),,,
,,,,,Asn397,,A2G2S2 (73 %); A3G3S3 (17 %); A3FG3S3 (6 %); FA2G2S2 (4 %),,,
,,,,,Asn588,,---,,,
,,,,,Asn762,,A2G2S2 (46 %); A3G3S3 (20 %); FA2G2S2 (16 %); A3FG3S3 (13 %); FA3FG3S3 (2 %); A4G4S4 (1 %); A4FG4S4 (1 %),,,
,,,,,Asn926,0 %,---,,,
Fibrinogen,,Coagulation (platelet aggregation),2.0–4.5,3,Overall,,A2G2S1(6) (53 %); A2G2S2(6) (33 %),,,"[59, 60, 67, 70, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117]"
Fibrinogen alpha-chain,P02671,,,,Asn453,0 %,---,,,
,,,,,Asn686,0 %,---,,,
Fibrinogen beta-chain,P02675,,,,Asn394,,A2G2S1(6); A2G2S2(6),,,
Fibrinogen gamma-chain,P02679,,,,Asn78,,A2G2S1(6); A2G2S2(6),,,
,,,,,Asn334,,A2G2S1(6); A2G2S2(6),Glycosylation_ in mutants,,
Haptoglobin,P00738,Scavenger of hemoglobin,0.8–2.5,1.32,Overall,,A2G2S2 (45 %); A2G2S1 (26 %); A3G3S3 (9 %); A3FG3S3 (6 %); A3G3S2 (5 %); A3G3S1 (5 %); A2FG2S1 (2 %); A2FG2S2 (1 %);,"Conc_, glycosylation complex, branching_, F_",,"[13, 118, 119, 120, 121, 122, 123, 124, 125, 126]"
,,,,,Asn184,97.7 %,A2G2S2 (46 %); A2G2S1 (38 %); A3G3S3 (4 %); A3G3S2 (3 %); A3G3S1 (2 %); A2FG2S2 (3 %); A2FG2S1 (3 %); A3FG3S3 (1 %),,,
,,,,,Asn207,97.4 %,A2G2S2 (47 %); A2G2S1 (39 %); A3G3S1 (7 %); A4G4S1 (2 %); A3FG3S1 (2 %); A4G4S2 (1 %); A2FG2S1 (1 %); A2FG2S2 (1 %),S_,,
,,,,,Asn211,98.5 %,"A2G2S2 (40 %); A3G3S3 (29 %), A3FG3S3 (21 %); A3G3S2 (10 %)",S_,,
,,,,,Asn241,95.8 %,A2G2S2 (47 %); A2G2S1 (26 %); A3G3S1 (10 %); A3G3S2 (8 %); A3G3S3 (4 %); A2FG2S1 (2 %); A2FG2S2 (1 %); A3FG3S2 (1 %); A4G4S1 (1 %);,,,
Hemopexin,P02790,Heme scavenger,0.4–1.5,0.8,Overall,,A2G2S2 (90 %); FA2G2S2 (5 %),"Conc_, Antennarity_, F_",Conc_,"[59, 60, 62, 67, 68, 70, 121, 127, 128, 129, 130, 131, 132, 133, 134]"
,,,,,Asn64,,A2G2S2(6) (90 %); FA2G2S2 (5 %),,,
,,,,,Asn187,,A2G2S2(6) (90 %); FA2G2S2 (5 %),,,
,,,,,Asn240,,,,,
,,,,,Asn246,,,,,
,,,,,Asn453,,A2G2S2(6) (90 %); FA2G2S2 (5 %),,,
Histdine-rich glycoprotein,P04196,"Immunity, coagulation and angiogenesis regulator",0.1–0.15,0.125,Overall,,A3-A4?,Conc_,Conc_,"[60, 70, 135, 136, 137, 138]"
,,,,,Asn63,,,,,
,,,,,Asn125,,,,,
,,,,,Asn344,,,,,
,,,,,Asn345,,,,,
Kininogen-1,P01042,Coagulation,0.055–0.090,0.0725,Overall,,"A3-A4?, core F",Sialyl-Lewis X_,,"[59, 60, 62, 67, 70, 139, 140]"
,,,,,Asn48,,core F,,,
,,,,,Asn169,,,,,
,,,,,Asn205,,core F,,,
,,,,,Asn294,,core F,,,
Serotransferrin,P02787,Iron transport,2–3,2.5,Overall,,A2G2S2 (96.5 %); FA2G2S2 (2.5 %); A3G3S2 (1 %),"Conc__ (pregnancy_, inflammation_), A3_(hepatoma), glycosylation changed (CDGs, alcohol_)",Conc_ (stable from 2yo),"[8, 59, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151]"
,,,,,Asn432,,A2G2S2 (93.5 %); A3G3S2 (2.5 %); A2G2S1 (2.4 %); A2FG2S2 (1.6 %),,,
,,Minor Asn-X-Cys site,,,Asn491,2 %,A2G2S2 (100 %),,,
,,,,,Asn630,,A2G2S2 (85.9 %); FA2G2S2 (6.9 %); A2FG2S2 (2.8 %); A2G2S1 (2.2 %); A3G3S2 (1.0 %); FA3G3S2 (0.9 %); FA2FG2S2 (0.3 %),,,
Vitronectin,P04004,"Cell adhesion, coagulation",0.2–0.4,0.3,Overall,,A2G2S2 (57 %); A3G3S3 (14.3 %); A3FG3S3 (10 %); A2G2S1 (8.7 %); Hy (6 %); FA2G2S2 (3.3 %),"Conc__ (inflammation_, liver fibrosis_), hybrid_(HCC), F_ (HCC)",,"[17, 59, 67, 70, 152, 153, 154]"
,,,,,Asn86,,A2G2S2 (45 %); A3G3S3 (33 %); A3FG3S3 (20 %),,,
,,,,,Asn169,,A2G2S2 (76 %); Hy (18 %); A2G2S1 (6 %),,,
,,,,,Asn242,,A2G2S2 (50 %); A2G2S1 (20 %); FA2G2S2 (10 %); A3G3S3 (10 %); A3FG3S3 (10 %),,,
Zinc-alpha-2-glycoprotein,P25311,Fat metabolism,0.05,0.05,Overall,,A2G2S2 (97 %); A2G2S1 (3 %),Conc_ (cancer),,"[59, 60, 67, 70, 96, 129, 155, 156, 157, 158]"
,,,,,Asn109,,,,,
,,,,,Asn112,,A2G2S2 (100 %),,,
,,,,,Asn128,,A2G2S2 (100 %),,,
,,,,,Asn259,,A2G2S2 (90 %); A2G2S1 (10 %),,,
Immunoglobulin A,,Immunity (mucosal; FcaRI),2.62,2.62,Overall,,A2G2S2 (24 %); A2G2S1 (20 %); FA2BG2S2 (14 %),,,"[159, 160, 161, 162, 163, 164, 165]"
IgA1,P01876,,,0.9,Asn144,,A2G2S1 (50 %); A2G2S2 (27 %); A2BG2S1 (10 %),,,
,,,,,Asn340,,FA2G2S2 (46 %); FA2BG2S2 (40 %); FA2G2S1 (13 %),,,
IgA2,P01877,,,0.1,Asn47,,,,,
,,,,,Asn92,,,,,
,,,,,Asn131,,,,,
,,,,,Asn205,,,,,
,,,,,Asn327,,,,,
Immunoglobulin D,P01880,Immunity,0.03; <0.003–0.4,0.035,Overall,,Man8 (14.4 %); Man9 (13.5 %); FA2G2S2 (7.6 %); FA2G2S1 (7.3 %); FA2BG2S2 (6.5 %); A2G2S1 (6.1 %),,,"[166, 167, 168, 169, 170]"
,,,,,Asn225,,Man8; Man9,,,
,,,,,Asn316,,FA2G2S2; FA2G2S1; FA2BG2S2; A2G2S1,,,
,,,,,Asn367,,FA2G2S2; FA2G2S1; FA2BG2S2; A2G2S1,,,
Immunoglobulin E,P01854,Immunity (parasitic infection; allergy),0.0003,0.0003,Overall,,FA2G2S2 (25 %); FA2G2S1 (14.5 %); FA2BG2S2 (13.5 %); FA2BG2S1 (13.5 %); Man5 (8.5 %),"B_, A3_",,"[169, 171, 172, 173, 174, 175, 176]"
,,,,,Asn21,,FA2G2S1 (30 %); FA2BG2S1 (30 %); FA2G2S2 (15 %); FA2BG2S2 (10 %),,,
,,,,,Asn49,,FA2G2S2 (30 %); FA2G2S1 (18 %); FA2BG2S2 (15 %); FA2BG2S1 (15 %),,,
,,,,,Asn99,,FA2G2S2 (40 %); FA2G2S1 (20 %),,,
,,,,,Asn146,,FA2G2S2 (50 %); FA2BG2S2 (30 %); FA2G2S1 (10 %),,,
,,,,,Asn252,,FA2BG2S1 (35 %); FA2BG2S2 (25 %); FA2G2S2 (15 %); FA2G2S1 (10 %),,,
,,,,,Asn264,0,---,,,
,,,,,Asn275,,Man5 (50 %); Man6 (15 %); Man7 (10 %); Man8 (10 %); Man9 (5 %),,,
Immunoglobulin G,,Immunity (primary; secondary; complement system),7–18,11.8,Overall,,FA2G1 (31 %); FA2G2 (23 %); FA2G2S1 (13 %); FA2 (10 %); FA2BG1 (5 %),"Conc_(pregnancy), FA2_, FA2G2_(RA, CD…), G_ + S_(pregnancy), G_",G_,"[19, 20, 24, 28, 33, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200]"
Immunoglobulin G1,P01857,,5.03,5.03,Asn180,,,,,
Immunoglobulin G2,P01859,,3.42,3.42,Asn176,,,,,
Immunoglobulin G3,P01860,,0.58,0.58,Asn227,,,,,
,,,0.58,0.58,Asn322,,,,,
Immunoglobulin G4,P01861,,0.38,0.38,Asn177,,,,,
Immunoglobulin M,P01871,Immunity (complement system),0.5–2.0,1.47,Overall,,FA2BG2S1 (26 %); FA2G2S1 (19 %); Man6 (10 %); Man5 (6 %),,,"[159, 201, 202, 203]"
,,,,,Asn46,,FA2BG2S1; FA2G2S1,,,
,,,,,Asn209,,FA2BG2S1; FA2G2S1,,,
,,,,,Asn272,,FA2BG2S1; FA2G2S1,,,
,,,,,Asn279,,Man5; Man6,,,
,,,,,Asn439,17,Man6; Man7; Man8,,,